Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 5, 2003, Pages 999-1004

  Sarich, T C ^a   Osende, J I ^b   Eriksson, U G ^c   Fager, G B ^c   Eriksson Lepkowska, M ^c   Ohlsson, L ^c   Carlsson, S ^c   Wahlander K ^b,d   Gustafsson, D ^c   Badimon, J J ^b  

^a ASTRAZENECA   (United Kingdom)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Direct thrombin inhibitor; R hirudin; Thrombus; Ximelagatran

Indexed keywords

EID: 0038174332     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00201.x     Document Type: Article

References (23)

1. Fenton JW, Ofosu FA, Brezniak DV, Hassouna HI. Thrombin and antithrombotics. Semin Thromb Hemost 1998; 24: 87-91.
2. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119: 95S-107S.
3. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
4. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353: 429-38.
5. Merlini PA, Ardissino D, Rosenberg RD, Colombi E, Agricola P, Oltrona L, Ottani F, Galvani M, Bauer KA, Bottasso B, Bertocchi F, Mannucci PM. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. Arterioscler Thromb Vasc Biol 2000; 20: 2162-6.
6. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359: 294-302.
7. Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Någard S, Abrahamsson A, Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
8. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, AhnoffM, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oreal direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; in press.
9. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sorensen H. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8.
10. Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87: 300-5.
11. Sarich TC, Wolzt M, Eriksson UG, Mattsson C, Schmidt A, Elg S, Andersson M, Wollbratt M, Fager G, Gustafsson D. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 2003; 41: 557-64.
12. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-52.
13. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998; 82: 12P-18P.
14. Klement P, Carlsson S, Liao P, Vlasin M, Stafford A, Johnston M, Rak J, Weitz JI. The benefit-to-risk profile of melagatran is superior to that of hirudin in rabbit arterial thrombosis prevention and bleeding models. J Thromb Haemost 2003; 1: 587-94.
15. Eriksson UG, Wollbratt M, Wolzt M, Svensson M, Grind M. Comparison of the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in patients with nonvalvular atrial fibrillation and elderly healthy subjects. Clin Pharmacol Therapeut 2002; 71: 95(Abstract).
16. Heit JA, ColwellCW, FrancisCW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21.
17. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-7.
18. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW. A randomized, double-blind, comparative study of ximelagatran and warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 2002; 137: 648-55.
19. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ. Statins and cardiovascular diseases: multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000; 153: 181-9.
20. Lev EI, Osende JI, Richard M, Robbins JA, Delfin JA, Rodriguez O, Sharma SK, Jayasundera T, Badimon JJ, Marmur JD. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. J Am Coll Cardiol 2001; 37: 847-55.
21. Osende J, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, Heflt G, Fallon JT, Crandall JP. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307-12.
22. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson BA. Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2002; 766: 47-55.
23. Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev 1995; 9: 143-56.